Wird geladen...
NIMG-30. ASSESSING TREATMENT RESPONSE OF GLIOBLASTOMA TO AN HDAC INHIBITOR, BELINOSTAT (PXD101)
The current standard of care for glioblastoma (GBM; WHO grade IV glioma) is maximal safe resection followed by radiation therapy (RT) with concurrent and adjuvant chemotherapy. Despite this aggressive treatment, the median survival remains only 15 months. Thus, there is a need for better treatment o...
Gespeichert in:
| Veröffentlicht in: | Neuro Oncol |
|---|---|
| Hauptverfasser: | , , , , , , , , , |
| Format: | Artigo |
| Sprache: | Inglês |
| Veröffentlicht: |
Oxford University Press
2017
|
| Schlagworte: | |
| Online Zugang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5692314/ https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/nox168.605 |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|